Cochrane · systematic review · CD010223
Selenium supplementation for Hashimoto's thyroiditis
van Zuuren, EJ, Albusta, AY, Fedorowicz, Z, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
3
No studies
3
Included studies
NR
No studies 3 · 50%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Selenium (+LT4) compared to placebo (+LT4) for participants with Hashimoto's thyroiditis
Population: participants with Hashimoto's thyroiditis.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change from baseline in health‐related quality of life Selenium (+LT4) vs placebo (+LT4) | no estimate extracted | NR | No studies |
Change from baseline in assessment of symptoms such as mood, fatigue and muscle weakness Short‐Form Health Survey Selenium (+LT4) vs placebo (+LT4) | RR 4.67 [1.61, 13.5] | 1 study · 36 participants | Low Downgraded: imprecision |
Proportion of participants reporting an adverse event Selenium (+LT4) vs placebo (+LT4) | RR 2.71 [0.29, 25.66] | 3 studies · 258 participants | Low |
Change from baseline in serum levels of anti‐thyroid peroxidase antibodies Decrease from 1508 to 25 IU/L Selenium (+LT4) vs placebo (+LT4) | no estimate extracted | 4 studies · 252 participants | Low |
Change from baseline in LT4 replacement dosage at end of study Selenium (+LT4) vs placebo (+LT4) | no estimate extracted | NR | No studies |
Economic costs Selenium (+LT4) vs placebo (+LT4) | no estimate extracted | NR | No studies |